publication venue for
- Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.. 4. 2023
- BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.. 3. 2022
- Brief Report: Contralateral Lobectomy for Second Primary NSCLC: Perioperative and Long-Term Outcomes.. 3. 2022
- Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors.. 3. 2022
- Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations.. 3. 2021
- Clinical Characteristics and Molecular Profiles of Lung Cancer in Ethiopia.. 2. 2021